Tirzepatide vs orforglipron: the injectable dual-agonist vs the oral GLP-1 pill
One is the largest-efficacy approved obesity drug; the other is the first small-molecule oral GLP-1 heading for FDA submission. Different tradeoffs for different patients.
Tirzepatide (Zepbound / Mounjaro) is the heaviest-hitting approved obesity drug of 2025, producing ~20% mean weight loss in Phase 3. Orforglipron is Eli Lilly's small-molecule oral GLP-1 agonist — the first pill-based GLP-1 to reach advanced Phase 3 and likely FDA submission. Orforglipron's weight-loss efficacy is modestly lower than tirzepatide's, but the oral route and supply-chain advantages are significant.
| Field | Tirzepatide | Orforglipron |
|---|---|---|
| Brand names | Mounjaro, Zepbound | Foundayo (expected brand) |
| Manufacturer | Eli Lilly | Eli Lilly |
| FDA approved | 2022 (T2D), 2023 (obesity) | Submitted (pending approval) |
| Indication | Type 2 diabetes, chronic weight management, OSA | Chronic weight management, type 2 diabetes (pending) |
| Mechanism | Dual GIP / GLP-1 receptor agonist (peptide) | Small-molecule GLP-1 receptor agonist (oral, non-peptide) |
| Delivery | Once-weekly subcutaneous injection | Oral daily tablet |
| Avg weight loss | ~20.9% at 72 weeks (SURMOUNT-1, 15 mg) | ~12-15% at Phase 3 durations (ATTAIN-1 top-line) |
Primary sources
- Tirzepatide: SURMOUNT-1 (NEJM, 2022)
- Orforglipron: Orforglipron Phase 2 (NEJM, 2023)
Frequently asked
Which one is more effective for weight loss?
Tirzepatide's SURMOUNT-1 (20.9% at 72 weeks) outperforms orforglipron's Phase 3 top-line (~12-15% at matched durations). They haven't been tested head-to-head yet.
What's the advantage of an oral GLP-1?
Convenience (no injection), no cold-chain storage, and critical for supply: small-molecule manufacturing scales more easily than peptide synthesis. The 2022-2025 GLP-1 shortage was a peptide-manufacturing bottleneck. Orforglipron doesn't have that constraint.
Is orforglipron the same as Rybelsus?
No. Rybelsus is oral semaglutide — still a peptide, with low oral bioavailability (~0.4-1%) that requires high-dose tablets taken in a fasted state with strict dosing instructions. Orforglipron is a small-molecule GLP-1 agonist, not a peptide, with typical small-molecule oral absorption.
When will orforglipron be available?
Lilly has indicated FDA approval expected late 2026 or 2027 pending regulatory review. It's not yet prescribable or on the market.